2-Aminoindane (2-AI) is a synthetic stimulant of the aminoindane chemical class — a family of bicyclic compounds structurally derived from indane, a molecule consisting of a cyclopentane ring fused to a benzene ring. The aminoindane class was originally developed in the 1990s as part of pharmaceutical research into safer non-neurotoxic stimulants, with 2-AI serving as the primary parent compound. Unlike amphetamine or methamphetamine, 2-aminoindane is generally believed to lack significant serotonin-releasing activity, which is associated with neurotoxic potential in fluorinated and substituted amphetamine analogs.
The subjective effects of 2-AI at typical doses are characterized as relatively mild compared to classical amphetamines — producing wakefulness, moderate focus enhancement, and gentle mood elevation without the cardiovascular intensity or compulsive redosing profile of methamphetamine or 4-FA. Community reports consistently describe it as a "subtle" stimulant, well-suited to low-intensity productivity tasks rather than recreational use, with a relatively clean headspace and modest side effect burden. Experience reports note that the onset is gradual and the duration moderate, typically 3–5 hours.
2-AI has attracted interest in the harm reduction community as a potential study aid given its purported non-neurotoxicity — the absence of the serotonergic releasing component that makes some fluorinated amphetamines potentially damaging with heavy use. However, this claim is based primarily on structural inference and animal studies; comprehensive human safety data remain unavailable. The substance is currently unscheduled in most jurisdictions, though some countries have implemented analog act coverage.
Safety at a Glance
High Risk- Route of Administration
- Do Not Combine with MAOIs
- Toxicity: Acute Toxicity No formal toxicological studies in humans have been published for 2-aminoindane. The acute toxicity pr...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Cocaine (+5 more)
- Overdose risk: Stimulant overdose from 2-Aminoindane is a medical emergency primarily involving cardiovascular a...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 1 hrs – 2 hrsHow It Feels
The onset of 2-aminoindane is gentle and unassuming. Thirty to forty-five minutes after ingestion, a faint stirring of energy surfaces in the chest, a mild quickening of the pulse that might easily be mistaken for a second cup of coffee. There is no rush, no sudden click of neurochemical engagement. Instead, the world simply becomes slightly more interesting: colors appear marginally crisper, ambient sounds register with a touch more clarity, and there is a subtle but definite increase in the desire to do things.
As the effects build over the next hour, a clean, modest stimulation settles in. Motivation gently rises, focus sharpens by a fraction, and conversations flow a little more easily. The body feels light but grounded, with none of the jittery tension that marks stronger stimulants. There may be a faint warmth in the extremities and a barely perceptible tightening of the jaw, but these sensations remain at the periphery of awareness. The mood lifts into a quiet optimism rather than outright euphoria. Tasks feel slightly more engaging, and there is a mild sociability that makes company pleasant without making solitude unbearable.
At the peak, reached roughly ninety minutes in, 2-aminoindane reveals itself as a substance of restraint. The stimulation is present but never overwhelming. Heart rate is mildly elevated, appetite is somewhat reduced, and there is a steady wakefulness that lacks the driven intensity of amphetamines. Some users report a faint empathogenic warmth, a softening of social edges that stops well short of the emotional openness associated with serotonergic compounds. Music sounds slightly better, physical movement feels slightly more fluid, and the general disposition is one of contented alertness.
The decline is as gradual as the onset. Over two to three hours, the mild energy slowly dissipates, replaced by a comfortable return to baseline. There is no crash, no rebound irritability, and no significant residual fatigue. Most users describe the experience as pleasant but unremarkable, a gentle nudge rather than a shove. Sleep comes without difficulty at the end of the evening.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(12)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temporary erectile dysfunction— Temporary erectile dysfunction is the substance-induced inability to achieve or sustain a penile ere...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Cognitive(15)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Memory enhancement— Memory enhancement is a state of improved mnemonic function in which past memories become unusually ...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
2-Aminoindane's pharmacology has not been formally characterized in human studies. Based on structural analysis and animal research, it is believed to act primarily as a dopamine and norepinephrine releasing agent, with substantially weaker serotonergic activity than amphetamine. This distinguishes it from its N-methyl analog (NM-2-AI) and from MDAI (5,6-methylenedioxy-2-aminoindane), which is more prominently serotonergic.
The aminoindane scaffold is rigid and conformationally constrained relative to the phenethylamine backbone of amphetamine. This rigidity is thought to reduce binding promiscuity and may contribute to the reportedly cleaner effect profile with lower cardiovascular activation than comparable amphetamines.
Receptor Profile
- DAT (dopamine transporter) — Primary substrate; releasing agent activity increases synaptic dopamine
- NET (norepinephrine transporter) — Secondary target; releasing activity produces wakefulness and vasoconstriction
- SERT (serotonin transporter) — Minimal activity, distinguishing 2-AI from entactogenic analogs and reducing neurotoxic risk
Pharmacokinetics
Formal pharmacokinetic data in humans are absent. Onset is reported at 30–60 minutes orally, with peak effects around 1–2 hours. Duration is typically 3–5 hours. The bicyclic structure likely affects hepatic metabolism compared to linear phenethylamines, but specific metabolic pathways are undocumented.
Tolerance
As with other dopaminergic stimulants, tolerance to 2-AI's effects is expected to develop with repeated use, though the rate and extent have not been systematically studied.
Detection Methods
Standard Drug Panel Inclusion
2-Aminoindane is an aminoindane-class stimulant that is not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. Its rigid bicyclic structure differs sufficiently from amphetamine that cross-reactivity with amphetamine immunoassays is unlikely. No dedicated immunoassay channel exists for aminoindane compounds.
Urine Detection
2-Aminoindane can be detected in urine for approximately 1 to 3 days after ingestion. The metabolic profile includes hydroxylated metabolites and conjugated derivatives excreted renally. Standard immunoassay urine screens will not detect this compound. Targeted analysis using LC-MS/MS with appropriate reference standards is required.
Blood and Saliva Detection
Blood detection windows for 2-aminoindane are estimated at 12 to 36 hours based on its pharmacokinetic profile. Oral fluid testing may detect the parent compound for a similar duration. Neither blood nor saliva testing panels routinely include aminoindane compounds.
Hair Follicle Detection
Hair follicle testing for 2-aminoindane is not available through standard commercial laboratories. The compound could theoretically be detected in hair using custom LC-MS/MS methods with reference standards, but this is not a practical concern as no testing program specifically targets aminoindanes.
Confirmatory Testing
GC-MS and LC-MS/MS are the definitive methods for identifying 2-aminoindane in biological specimens. The rigid bicyclic structure produces characteristic fragmentation patterns in mass spectrometry that can distinguish it from amphetamines and other stimulant classes. Reference standards are commercially available from forensic chemistry suppliers.
Reagent Testing
Marquis reagent produces no significant reaction or a faint yellow color with 2-aminoindane, which distinguishes it from amphetamines (orange-brown) and MDMA (purple-black). Mecke reagent shows no reaction. Simon's reagent is negative (primary amine). These negative or weak reactions help rule out common substances but cannot confirm identity.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Cocaine | Dangerous | — |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Dangerous | — |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Origins in Aminoindane Research
The aminoindane class was developed in the late 1980s and 1990s as part of research into rigid phenethylamine analogs. The structural constraint of fusing a cyclopentane ring onto the benzene of a phenethylamine backbone was intended to probe the steric requirements of monoamine transporters and receptors. 2-Aminoindane itself appeared in academic literature primarily as a pharmacological reference compound.
Relationship to MDAI and Designer Drug Context
The broader aminoindane family gained notoriety when 5,6-methylenedioxy-2-aminoindane (MDAI) — a more serotonergic, MDMA-like aminoindane — emerged as a designer drug in the early 2010s. Several aminoindane derivatives, including MDAI and 5-IAI, were marketed as "legal ecstasy" alternatives in the UK and Europe. This drew regulatory attention to the class.
2-AI itself attracted less notoriety due to its more modest, predominantly dopaminergic profile, remaining in the broader research chemical stimulant market rather than the entactogen market. It continues to circulate as an unscheduled (in most jurisdictions) research chemical, of interest primarily to harm reduction-oriented users who prioritize lower neurotoxic potential over recreational potency.
Harm Reduction
Start Low
Due to the near-total absence of formal dosage studies, starting low is essential. Community-reported threshold doses are approximately 20–40 mg orally. Incremental increases are warranted given the limited data on dose-response relationships.
Route of Administration
Oral administration is recommended. Insufflation data are sparse; the aminoindane scaffold may produce irritation, and the advantage in bioavailability is unclear. Avoid intravenous use entirely — sterility and dosing precision are impossible with research chemical powders.
Do Not Combine with MAOIs
As with any releasing agent, combination with monoamine oxidase inhibitors risks serotonin syndrome or hypertensive crisis. This includes both pharmaceutical MAOIs (phenelzine, tranylcypromine) and reversible inhibitors (moclobemide).
Cardiovascular Caution
Avoid use with pre-existing cardiovascular conditions, hypertension, or arrhythmias. Do not combine with other stimulants or vasoconstrictors.
Avoid Redosing
The gradual onset of 2-AI makes premature redosing a significant risk. Allow the full duration to elapse before considering any second dose.
No Long-Term Use Data
The "non-neurotoxic" designation for 2-AI is based on animal studies and structural inference. It should not be interpreted as long-term safety clearance. Chronic daily use has no documented safety profile.
Toxicity & Safety
Acute Toxicity
No formal toxicological studies in humans have been published for 2-aminoindane. The acute toxicity profile is unknown. Based on its structural class and proposed mechanism (primarily dopaminergic/noradrenergic releasing), the risks are broadly comparable to other stimulants of similar potency — primarily cardiovascular and psychological rather than directly neurotoxic.
Neurotoxicity
The primary research interest in aminoindanes has been their potential non-neurotoxicity compared to 4-substituted amphetamines. Studies in animals suggest that 2-AI does not produce the serotonergic neurotoxicity associated with MDMA or 4-FA at high doses. However, these findings cannot be uncritically translated to human use, and the absence of serotonin releasing activity does not eliminate all toxicity risks.
Cardiovascular Risk
As a releasing agent acting on norepinephrine and dopamine, 2-AI produces sympathomimetic cardiovascular effects — elevated heart rate, blood pressure, and vasoconstriction. These are less pronounced than amphetamine equivalents at reported typical doses, but remain meaningful risk factors for those with cardiovascular disease.
Psychological Risks
Stimulant-class psychological risks apply: anxiety, agitation, insomnia, and with heavy use, potential for stimulant psychosis. Community experience reports note that overdose presents primarily as overwhelming stimulation rather than entactogenic crisis.
Comedown
User reports describe a moderate comedown — fatigue and low motivation for 12–24 hours following use — consistent with acute dopamine depletion after a releasing agent. Comedowns are described as less severe than after amphetamine or 4-FA.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from 2-Aminoindane is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
2-AI is currently believed to be a grey area compound within most parts of the world. This means that it is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
Austria: 2-AI is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
China: 2-AI is a controlled substance.
Germany: 2-AI is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland: 2-AI is a controlled substance specifically named under Verzeichnis E.
United Kingdom: 2-AI is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
Responsible use
Stimulants
2-AI (Wikipedia)
2-AI (Erowid Vault)
2-Aminoindane (Isomer Design)
Experience Reports (2)
Tips (5)
Monitor your heart rate and blood pressure when using 2-Aminoindane. Sustained elevated cardiovascular stress causes cumulative damage. If you experience chest pain, irregular heartbeat, or numbness in extremities, seek medical attention.
Weigh your dose of 2-Aminoindane with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
Avoid binge patterns with 2-Aminoindane. Sleep deprivation combined with stimulant use dramatically increases psychosis risk after 48+ hours awake. If you find yourself redosing to avoid the comedown, that is a major warning sign.
If you snort 2-Aminoindane, use a clean straw (never shared), crush the powder as finely as possible, alternate nostrils, and rinse with saline spray after your session. Chronic insufflation damages nasal tissue and septum.
Do not take 2-Aminoindane in the afternoon or evening if you want to sleep that night. Most stimulants have long half-lives and even if you feel you can sleep, the quality will be significantly impaired.
See Also
References (3)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- 2-Aminoindane - TripSit Factsheet
TripSit factsheet for 2-Aminoindane
tripsit - 2-Aminoindane - Wikipedia
Wikipedia article on 2-Aminoindane
wikipedia